WO2012047800A1 - Methods for increasing muscle glucose uptake and decreasing muscle recovery time using amino acid blend - Google Patents
Methods for increasing muscle glucose uptake and decreasing muscle recovery time using amino acid blend Download PDFInfo
- Publication number
- WO2012047800A1 WO2012047800A1 PCT/US2011/054592 US2011054592W WO2012047800A1 WO 2012047800 A1 WO2012047800 A1 WO 2012047800A1 US 2011054592 W US2011054592 W US 2011054592W WO 2012047800 A1 WO2012047800 A1 WO 2012047800A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- body weight
- amino acid
- muscle
- individual
- acid blend
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 187
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 109
- 238000000034 method Methods 0.000 title claims abstract description 67
- 210000003205 muscle Anatomy 0.000 title claims abstract description 57
- 230000004190 glucose uptake Effects 0.000 title claims abstract description 38
- 238000011084 recovery Methods 0.000 title claims abstract description 16
- 230000003247 decreasing effect Effects 0.000 title abstract description 5
- 229940024606 amino acid Drugs 0.000 claims abstract description 108
- 235000001014 amino acid Nutrition 0.000 claims abstract description 108
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims abstract description 36
- 229960000310 isoleucine Drugs 0.000 claims abstract description 36
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims abstract description 36
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 32
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 32
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 32
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 32
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229930182817 methionine Natural products 0.000 claims abstract description 32
- 239000004474 valine Substances 0.000 claims abstract description 32
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 31
- 235000018417 cysteine Nutrition 0.000 claims abstract description 30
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims abstract description 17
- 230000037396 body weight Effects 0.000 claims description 65
- 150000001720 carbohydrates Chemical class 0.000 claims description 36
- 235000014633 carbohydrates Nutrition 0.000 claims description 34
- 235000018102 proteins Nutrition 0.000 claims description 27
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 27
- 210000000663 muscle cell Anatomy 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 7
- 239000000835 fiber Substances 0.000 claims description 7
- 239000000796 flavoring agent Substances 0.000 claims description 7
- 235000019634 flavors Nutrition 0.000 claims description 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 6
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 5
- 239000004472 Lysine Substances 0.000 claims description 5
- 239000004473 Threonine Substances 0.000 claims description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 235000003704 aspartic acid Nutrition 0.000 claims description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
- 235000019197 fats Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 24
- 239000008103 glucose Substances 0.000 abstract description 24
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 15
- 210000004369 blood Anatomy 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 12
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract description 9
- 230000007423 decrease Effects 0.000 abstract description 5
- 239000007788 liquid Substances 0.000 description 31
- 239000000243 solution Substances 0.000 description 26
- 229960003136 leucine Drugs 0.000 description 25
- 229960004295 valine Drugs 0.000 description 25
- 239000000047 product Substances 0.000 description 20
- 239000004615 ingredient Substances 0.000 description 18
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 18
- 210000002027 skeletal muscle Anatomy 0.000 description 16
- 241000700159 Rattus Species 0.000 description 10
- 230000006377 glucose transport Effects 0.000 description 10
- 235000016709 nutrition Nutrition 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 230000004153 glucose metabolism Effects 0.000 description 9
- 229940125396 insulin Drugs 0.000 description 9
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 235000021074 carbohydrate intake Nutrition 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 239000011536 extraction buffer Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 238000007410 oral glucose tolerance test Methods 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 208000002705 Glucose Intolerance Diseases 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000021073 macronutrients Nutrition 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 201000009104 prediabetes syndrome Diseases 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 235000011888 snacks Nutrition 0.000 description 4
- 239000012086 standard solution Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 239000004386 Erythritol Substances 0.000 description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 206010028289 Muscle atrophy Diseases 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 235000005822 corn Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 235000019414 erythritol Nutrition 0.000 description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 3
- 229940009714 erythritol Drugs 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000000845 maltitol Substances 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 3
- 229940035436 maltitol Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 201000000585 muscular atrophy Diseases 0.000 description 3
- 210000003098 myoblast Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 208000001076 sarcopenia Diseases 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000012265 solid product Substances 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- FBPFZTCFMRRESA-JYKPICNFSA-N (2s,3s,4r,5r)-hexane-1,2,3,4,5,6-hexol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)[14CH2]O FBPFZTCFMRRESA-JYKPICNFSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 238000005462 in vivo assay Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 235000021486 meal replacement product Nutrition 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 239000013588 oral product Substances 0.000 description 2
- 229940023486 oral product Drugs 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000002600 sunflower oil Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000000153 supplemental effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 1
- PMMURAAUARKVCB-CERMHHMHSA-N 2-deoxy-D-glucopyranose Chemical compound OC[C@H]1OC(O)C[C@@H](O)[C@@H]1O PMMURAAUARKVCB-CERMHHMHSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000012371 Aseptic Filling Methods 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- NEAPKZHDYMQZCB-UHFFFAOYSA-N N-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]ethyl]-2-oxo-3H-1,3-benzoxazole-6-carboxamide Chemical compound C1CN(CCN1CCNC(=O)C2=CC3=C(C=C2)NC(=O)O3)C4=CN=C(N=C4)NC5CC6=CC=CC=C6C5 NEAPKZHDYMQZCB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 235000019742 Vitamins premix Nutrition 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- -1 acidulants Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000015496 breakfast cereal Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 238000000641 cold extrusion Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000021183 entrée Nutrition 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 235000019534 high fructose corn syrup Nutrition 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000012171 hot beverage Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 206010021654 increased appetite Diseases 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 238000011684 zucker rat (obese) Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present disclosure relates to methods for increasing muscle glucose uptake and decreasing muscle recovery time by administration of a composition comprising select amino acid blends.
- Glucose uptake and transport into muscle cells may also be particularly important for the pre-diabetic and diabetic population, as it is well known that a decrease in muscle glucose uptake is one of the early symptoms of diabetes.
- pre-diabetics and diabetics can more easily maintain a steady level of blood glucose and avoid unwanted glucose spikes.
- the rate of glucose uptake into muscle cells has been primarily enhanced by the use of exogenous insulin, physical exertion and exercise, and/or carbohydrate loading. Although one or a combination of these options may result in an increase uptake of glucose into muscle cells and the resulting benefits, they may not be suitable for all adults. For example, hypoglycemic episodes may be associated with insulin use in some adults. Additionally, not all adults have the physical ability to perform exercise, nor the physical ability to ingest a large number of carbohydrate calories.
- compositions and methods for easily and effectively increasing the uptake of glucose into muscle tissue and reduce muscle recovery time. Additionally, it would be very beneficial if the compositions and methods could be utilized by a wide variety of adults, irrespective of overall health condition and physical ability.
- the present disclosure is directed to methods of increasing muscle glucose uptake and improving muscle glucose metabolism by administering a composition including a specific amino acid blend comprising isoleucine, leucine, valine, methionine, and cysteine.
- a composition including a specific amino acid blend comprising isoleucine, leucine, valine, methionine, and cysteine.
- the specific amino acid blend is utilized to increase the muscle recovery rate of an individual.
- the present disclosure is specifically directed to a method of increasing glucose uptake in a muscle cell of an individual.
- the method comprises administering to the individual a composition comprising an amino acid blend comprising isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of about 97.65 :about 0.68:about 0.77:about 0.31 :about 0.59, respectively.
- the present disclosure is further directed to a method of increasing the muscle recovery rate of an individual.
- the method comprises administering to the individual a composition comprising an amino acid blend comprising isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of about 97.65 :about 0.68:about
- the present disclosure is further directed to a method of increasing the muscle glucose metabolism rate of an individual.
- the method comprises administering to the individual a composition comprising an amino acid blend comprising isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of about 97.65 :about 0.68:about 0.77:about 0.31 :about 0.59, respectively.
- the present disclosure is further directed to a method of managing or treating diabetes or prediabetes in an individual.
- the method comprises administering to the individual a composition comprising an amino acid blend comprising isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of about 97.65 :about 0.68:about 0.77:about 0.31 :about 0.59, respectively.
- the present disclosure is further directed to a method of managing or treating insulin resistance in an individual.
- the method comprises administering to the individual a composition comprising an amino acid blend comprising isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of about 97.65 :about 0.68:about
- the present disclosure is further directed to a method of preventing or treating skeletal muscle loss in an individual.
- the method comprises administering to the individual a composition comprising an amino acid blend comprising isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of about 97.65 :about 0.68:about
- the present disclosure is further directed to a method of increasing glucose uptake in a muscle cell of a diabetic athlete.
- the method comprises administering to the individual a composition comprising an amino acid blend comprising isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of about 97.65 :about 0.68:about 0.77:about 0.31 :about 0.59, respectively.
- the glucose uptake, and hence the glucose metabolism rate, in muscle cells can be increased such that the time period for muscle recovery after a trauma or physical activity, such as after a workout, is reduced.
- the specific amino acid blend increases glucose transport into muscle cells and reduces or eliminates that need for other means of increasing glucose transport into muscle cells, such as insulin use or ingestion of large amounts of
- the specific amino acid blend is particularly useful for prediabetics and diabetics as they typically experience a significant decrease in muscle glucose metabolism as diabetes progresses.
- these individuals can increase muscle glucose uptake, which allows them to control their blood glucose level without solely relying on insulin or methodologies that can interfere with digestion.
- Figure 1 is a graph showing the glucose uptake in red and white gastrocnemius muscles from Sprague-Dawley rats during an oral glucose tolerance test.
- Figure 2 is a graph showing the glucose uptake in red gastrocnemius muscles from Zucker obese rats during an oral glucose tolerance test.
- Figure 3 is a graph showing the glucose uptake in the soleus muscle from Zucker obese rats during an oral glucose tolerance test.
- Figure 4 is a graph showing the glucose uptake in response to the treatment of epitrochlearis muscles from rats with different doses of a specific amino acid blend.
- Figure 5 is a graph showing the C2C12 myotubular glucose transport in response to treatment with various amino acid blends.
- compositions and methods of the present disclosure are directed to specific blends of amino acids including isoleucine, leucine, valine, methionine, and cysteine for increasing the rate of muscle glucose uptake and metabolism.
- the term "healthy individual” as used herein refers to a person who is in generally good health, and is not obese, a prediabetic or diabetic.
- diabetes athlete refers to an athlete who is diabetic, prediabetic, or suffers from impaired glucose tolerance.
- compositions of the present disclosure may also be substantially free of any optional or selected essential ingredient or feature described herein, provided that the remaining composition still contains all of the required ingredients or features as described herein.
- substantially free means that the selected composition contains less than a functional amount of the optional ingredient, typically less than 0.1% by weight, and also including zero percent by weight of such optional or selected essential ingredient.
- compositions and corresponding methods of the present disclosure can comprise, consist of, or consist essentially of the essential elements and limitations of the disclosure as described herein, as well as any additional or optional ingredients, components, or limitations described herein or otherwise useful in the compositions or methods.
- compositions including the specific amino acid blends useful in the methods of the present disclosure may be formulated in any known or otherwise suitable product form for oral or parenteral administration.
- Oral product forms are generally preferred and include any solid, liquid, or powder formulation suitable for use herein, provided that such a formulation allows for safe and effective oral delivery of the essential and other selected ingredients from the selected product form.
- Non-limiting examples of solid nutritional product forms suitable for use herein include snack and meal replacement products, including those formulated as bars, sticks, cookies or breads or cakes or other baked goods, frozen liquids, candy, breakfast cereals, powders or granulated solids or other particulates, snack chips or bites, frozen or retorted entrees and so forth.
- liquid product forms suitable for use herein include snack and meal replacement products, hot or cold beverages, carbonated or non carbonated beverages, juices or other acidified beverages, milk or soy-based beverages, shakes, coffees, teas, enteral feeding compositions, and so forth.
- compositions are most typically formulated as suspensions or emulsions, but can also be formulated in any other suitable forms such as clear liquids, solutions, liquid gels, and so forth.
- suitable oral product forms include semisolid or semi-liquid compositions (e.g., puddings, gels), as well as more conventional product forms such as capsules, tablets, caplets, pills, and so forth.
- the quantity of the composition for providing an effective amount of the defined amino acid blend to the targeted user may be contained in one or a plurality of individual dosage forms, e.g., in one tablet or a plurality of tablets that may be administered in single or multiple dosages per day.
- the amino acid blend may be formulated at concentrations most typically ranging from about 5 to about 50%, including from about 15 to about 33%, and also including from about 15 to about 25%, by weight of the product form, all in combination with excipients or other ingredients such as carbohydrates, acidulants, flavors, and colors.
- compositions useful in the methods of the present disclosure comprise a select blend of branched chain amino acids and sulfur-containing amino acids, the former of which includes valine (VAL), leucine (LEU), and isoleucine (ILE), and the latter of which includes cysteine (CYS) and methionine (MET).
- the compositions include a specific amino acid blend of at least isoleucine, leucine, valine, cysteine, and methionine, the quantity or amount of which should be sufficient to provide an increase in glucose uptake in a muscle cell of an individual, an increase in the muscle recovery rate of an individual, and/or an increase in muscle glucose metabolism rate in an individual upon administration.
- the amino acid blend is present in the composition in an amount sufficient to provide an individual with from about 0.1 grams to about 50 grams per day, desirably from about 1 gram to about 15 grams per day of the amino acid blend.
- the composition may be administered once, twice, three times or more daily to reach the desired level of amino acid blend intake per day.
- the amino acid blend comprises isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of about 97.65 :about 0.68:about
- the amino acid blend comprises isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of 96.49- 98.00:0.65-0.70:0.68-0.81 :0.26-0.38:0.55-0.62, respectively.
- the composition contains from about 1.0 to about 200 mg/kg of body weight of isoleucine; from about 0.001 to about 10 mg/kg of body weight of leucine; from about 0.001 to about 10 mg/kg of body weight of valine; from about 0.001 to about 10 mg/kg of body weight of cysteine; and from about 0.001 to about 10 mg/kg of body weight of methionine.
- Body weight refers to body weight of the individual or subject patient to which the composition is administered.
- the composition contains from about 120 to about 180 mg/kg of body weight of isoleucine; from about 0.25 to about 7.5 mg/kg of body weight of leucine; from about 0.25 to about 7.5 mg/kg of body weight of valine; from about 0.25 to about 7.5 mg/kg of body weight of cysteine; and from about 0.2 to about 5 mg/kg of body weight of methionine.
- the composition contains from about 130 to about 170 mg/kg of body weight of isoleucine; from about 0.5 to about 5 mg/kg of body weight of leucine; from about 0.5 to about 5 mg/kg of body weight of valine; from about 0.5 to about 5 mg/kg of body weight of cysteine; and from about 0.3 to about 3 mg/kg of body weight of methionine.
- the amount of amino acids for use in the select amino acid blends may also be characterized as a weight ratio of the branched chain to sulfur-containing amino acids of at least about 10: 1 , including at least about 50: 1 , and also including at least about 100: 1 , and also including from 500: 1 to 10: 1.
- the individual amino acids for use in the compositions and methods of the present disclosure can be provided in the form of natural, intact or hydrolyzed proteins, which may therefore include free amino acids as well as various polypeptides or intact proteins within the compositions or otherwise consumed as part of the methods, provided that such sources provide the requisite kind and amount of amino acids in the blends as described herein.
- the amino acid blends for use in the methods and composition may therefore comprise from 0 to 100% , including from 50 to 100%, also including from 75 to 95%), also including from 90 to 100%, and also including 100%, on a molar or weight basis of the targeted amino acid blend in the form of free amino acids within the compositions or otherwise administered in the methods.
- the amino acid blends may also be provided in the form of a blend of one or more of free amino acids, intact proteins, and hydrolyzed proteins or other protein fractions.
- the amino acids in the defined blend may be in the L or R configuration, or a mixture thereof, although most amino acids for use in the formulation will typically be in the L configuration. Suitable amino acids described herein are commercially available from a number of different material suppliers, including Sigma- Aldrich Corporation (St. Louis, Missouri.) [0045]
- the pH of the liquid composition is suitable for appropriate administration to a subject, such as by oral administration.
- the composition has a pH of from about 2.5 to about 8.0, including from about 2.7 to about 7.0, and also including from about 3.0 to about 5.5, and also including from about 3.0 to about 5.0.
- compositions of the present disclosure may further comprise one or more supplemental amino acids, non-limiting examples of which include aspartic acid (ASP), threonine (THR), serine (SER), glutamic acid (GLU), proline (PRO), glycine (GLY), alanine (ALA), tyrosine (TYR), histidine (HIS), lysine (LYS), arginine (ARG), tryptophan (TRY), phenylalanine (PHE), and combinations thereof.
- supplemental amino acids include aspartic acid (ASP), threonine (THR), serine (SER), glutamic acid (GLU), proline (PRO), glycine (GLY), alanine (ALA), tyrosine (TYR), histidine (HIS), lysine (LYS), arginine (ARG), tryptophan (TRY), phenylalanine (PHE), and combinations thereof.
- the compositions may contain a sufficient amount of one or more (such
- the composition contains one or more of from about 0.01 to about 30 mg/kg (including from about 1 to about 30 mg/kg and also including from about 5 to about 20 mg/kg) of body weight of each of aspartic acid and glutamic acid; from about 0.001 to about 10 mg/kg (including from about 0.1 to about 10 mg/kg and also including from about 0.5 to about 5 mg/kg) of body weight of each of threonine, serine, proline, histidine, and lysine; and from about 0.001 to about 20 mg/kg (including from about 0.1 to about 20 mg/kg and also including from about 1 to about 10 mg/kg) of body weight of each of glycine, alanine, tyrosine, arginine, and tryptophan.
- the compositions of the present disclosure contain little or no phenylalanine.
- the composition may contain less than about 10 mg/kg of body weight of phenylalanine or less than about 5% by weight.
- the composition contains less than about 5 mg/kg of body weight of phenylalanine.
- the composition contains zero or less than about 1 mg/kg of body weight of phenylalanine.
- compositions of the present disclosure including the amino acid blend may further comprise one or more other macronutrients including a fat source, a carbohydrate source, and a protein source, all in addition to the amino acid blend as described herein.
- the optional macronutrients in combination with the other essential or added ingredients may provide up to about 1000 kcal of energy per serving or dose, including from about 25 kcal to about 900 kcal, also including from about 75 kcal to about 700 kcal, also including from about 100 kcal to about 500 kcal, also including from about 150 kcal to about 400 kcal, and also including from about 200 kcal to about 300 kcal, per serving or dose, most suitably as a single, undivided serving or dose.
- Carbohydrates suitable for use in the compositions of the present disclosure may be simple, complex, or variations or combinations thereof.
- suitable carbohydrates include hydrolyzed or modified starch or cornstarch, maltodextrin, glucose polymers, sucrose, corn syrup, corn syrup solids, rice-derived carbohydrate, glucose, fructose, lactose, high fructose corn syrup, indigestible
- oligosaccharides e.g., fructooligosaccharides
- soluble or insoluble fiber honey
- sugar alcohols e.g., maltitol, erythritol, sorbitol
- Proteins suitable for use in the compositions include hydrolyzed, partially hydrolyzed or non- hydrolyzed proteins or protein sources, and can be derived from any known or otherwise suitable source such as milk (e.g., casein, whey), animal (e.g., meat, fish), cereal (e.g., rice, corn), vegetable (e.g., soy), or combinations thereof.
- milk e.g., casein, whey
- animal e.g., meat, fish
- cereal e.g., rice, corn
- vegetable e.g., soy
- Fats suitable for use in the compositions include coconut oil, fractionated coconut oil, soy oil, corn oil, olive oil, safflower oil, high oleic safflower oil, MCT oil (medium chain triglycerides), sunflower oil, high oleic sunflower oil, palm and palm kernel oils, palm olein, canola oil, marine oils, cottonseed oils, structured lipids, and combinations thereof.
- compositions of the present disclosure may vary considerably depending upon the particular product form (e.g., solid, liquid, powder) and the various other formulations and targeted dietary needs. These macronutrients are most typically formulated within any of the caloric ranges (embodiments A-D) described in the following table.
- compositions including the amino acid blend of the present disclosure may further comprise other optional components that may modify the physical, chemical, aesthetic or processing characteristics of the products or serve as pharmaceutical or additional nutritional components when used in the targeted population.
- optional ingredients are known or otherwise suitable for use in medical food or other nutritional products or pharmaceutical dosage forms and may also be used in the compositions herein, provided that such optional ingredients are safe for oral
- Non-limiting examples of such optional ingredients include fibers, preservatives, anti-oxidants, emulsifying agents, buffers, pharmaceutical actives, additional nutrients as described herein, colorants, flavorants, thickening agents and stabilizers, emulsifying agents, lubricants, sweetening agents, vitamins, minerals and so forth.
- compositions including the specific amino acid blends of the present disclosure may be prepared by any known or otherwise effective manufacturing technique for preparing the selected product form. Many such techniques are known for any given product form such as nutritional liquids or nutritional bars and can easily be applied by one of ordinary skill in the art to the nutritional products described herein.
- compositions can likewise be prepared by any known or otherwise effective manufacturing technique for preparing the various pharmaceutical product forms. Many such techniques are known for any given pharmaceutical product form such as capsules, tablets, liquids, and so forth, and can easily be applied by one of ordinary skill in the art to the compositions described herein.
- compositions may be prepared by dissolving each of the selected amino acids in water or a dilute acid solution, and then combining the different amino acid solutions to form a liquid embodiment of the present disclosure.
- the compositions may be prepared by combining the different powder forms of the selected amino acids, along with any tablet forming materials or other excipients, and then dry blending the powders prior to processing it into the desired solid product form, e.g., tablet, capsule, caplet, and so forth.
- compositions may be formulated as a nutritional liquid, including a juice or milk or soy-based liquid, comprising the selected amino acid blend.
- a nutritional liquid including a juice or milk or soy-based liquid, comprising the selected amino acid blend.
- Such an embodiment may be prepared by first forming an oil and fiber blend containing all formulation oils, any emulsifier, fiber and fat-soluble vitamins.
- Additional slurries (typically a carbohydrate and two protein slurries) are prepared separately by mixing the carbohydrate and minerals together and the protein in water. The slurries are then mixed together with the oil blend. The resulting mixture is homogenized, heat processed, standardized with any water-soluble vitamins, flavored and the liquid terminally sterilized or aseptically filled or dried to produce a powder.
- the solid product is then coated, to enhance palatability, and packaged for distribution.
- the fat-soluble components are then blended together and mixed with any powdered premixes.
- any liquid components are then mixed into the composition, forming a plastic like composition or dough.
- the resulting plastic mass can then be shaped, without further physical or chemical changes occurring, by cold forming or extrusion, wherein the plastic mass is forced at relatively low pressure through a die, which confers the desired shape.
- the resultant exudate is then cut off at an appropriate position to give products of the desired weight. If desired the solid product is then coated, to enhance palatability, and packaged for distribution.
- the solid nutritional embodiments of the present invention may also be manufactured through a baked application or heated extrusion to produce solid product forms such as cereals, cookies, crackers, and similar other product forms.
- solid product forms such as cereals, cookies, crackers, and similar other product forms.
- compositions may, of course, be manufactured by other known or otherwise suitable techniques not specifically described herein without departing from the spirit and scope of the present invention.
- present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive and all changes and equivalents also come within the description of the present invention.
- compositions including the specific amino acid blend as described herein may be administered to individuals to increase the rate of glucose uptake in a muscle cell of the individual, to increase the rate of muscle recovery rate of an individual, to increase the rate of muscle glucose metabolism in an individual, or to increase the fuel supply to the muscles of an individual.
- the individual may be a healthy individual, such as an athlete, who wants to speed muscle recovery after a trauma or physical exertion.
- the individual may be an individual who is a prediabetic or has diabetes, has insulin resistance, or impaired glucose tolerance, or who wants to control and maintain safe blood glucose levels with the use of little or no insulin.
- the individual may be an individual who suffers from skeletal muscle loss, cancer cachexia, sarcopenia,
- HIV/AIDS HIV/AIDS, COPD, or a combination thereof.
- compositions and methods of the present disclosure may be directed to any individual, including humans and other mammals such dogs, cats, rodents, cows, sheep, swine, goats, horses and other hoofed animals, and so forth. Healthy individuals at risk of type 2 diabetes may be administered the compositions as well.
- compositions including the specific amino acid blend may be administered before, during, or after carbohydrate intake (such as from a meal, drink, or snack), or before, during or after exercise to increase the rate of muscle recovery and/or increase muscle glucose metabolism rates.
- carbohydrate intake such as from a meal, drink, or snack
- administration of the amino acid composition is conducted within about one hour of carbohydrate consumption and/or physical exertion by the subject.
- the administration of the amino acid composition is conducted within about 30 minutes of carbohydrate
- compositions including the specific amino acid blend may be used to increase muscle uptake of blood glucose to treat and/or manage glucose tolerance, diabetes, obesity, skeletal muscle loss, sarcopenia, muscle wasting diseases, cachexia due to cancer, HIV/ AIDS, COPD and combinations thereof, and/or symptoms and side effects thereof.
- the compositions and methods may be used to treat type 1 diabetes, type 2 diabetes and/or symptoms thereof.
- Symptoms and side effects of diabetes include one or more of high blood glucose levels, sleep habits such as insomnia, general energy level such as lethargy, decreased strength, body weight/poor or increased appetite, reflux, irregularity, stomach neuropathy, kidney failure, heart disease, stroke, and deteriorating eyesight.
- the methods of the present disclosure as described herein are also intended to include the use of such methods in individuals unaffected by or not otherwise afflicted with glucose intolerance, diabetes, obesity, sarcopenia, muscle wasting diseases, etc., for the purpose of managing, preventing, minimizing, or delaying the development of such diseases or conditions over time.
- the methods of the present disclosure preferably include continuous, daily administration of the compositions as described herein.
- Such preventive methods may be directed at adults or others who are at risk of developing muscle wasting and/or diabetes.
- administering increases muscle glucose metabolism.
- Blood glucose levels may be determined using whole blood, blood plasma or blood serum. Unless otherwise indicated, blood glucose levels refer to analysis of whole blood.
- Administration of the compositions decreases blood glucose levels after carbohydrate ingestion (compared to blood glucose levels after carbohydrate ingestion without administration of the amino acid compositions) in at least one of about 30 minutes after carbohydrate intake, about 60 minutes after carbohydrate intake, about 90 minutes after carbohydrate intake, and about 120 minutes after
- the rate of glucose uptake in red gastrocnemius and white gastrocnemius muscles of Sprague-Dawley rats is analyzed following the administration of: (1) a carbohydrate-only solution; or (2) a carbohydrate solution including a specific amino acid blend of the present disclosure.
- the carbohydrate-only solution administered is a 22.5% (by weight) glucose standard solution.
- the carbohydrate solution including a specific amino acid blend is a 22.5%) (by weight) glucose standard solution (50 mL) including 5.28 mg of cysteine, 3.36 mg of methionine, 6.68 mg of valine, 944.8 mg of isoleucine, and 6.58 mg of leucine.
- the amino acid blend is introduced into 45 mL of the 22.5% glucose solution while stirring at high speed for about 1.5 hours. After all of the amino acids are dissolved, the solution is brought up to 50 mL.
- the amino acid blend has a molar ratio of
- isoleucine leucine : valine methionine: cysteine of about 97.65:0.68:0.77:0.31 :0.59.
- Sprauge Dawley rats are orally gavaged 8 ml/kg with either carbohydrate (CHO) or carbohydrate plus the 5 amino acid mixture (CHO-AA). Fifteen minutes after the gavage, a bolus containing 40 ⁇ 3 ⁇ 4 body weight 2-[l,2- 3 H] deoxyglucose ( 3 H-2-DG) and 20 ⁇ 3 ⁇ 4 body weight [U- 14 C] mannitol is injected by syringe via a tail vein.
- CHO carbohydrate
- CHO-AA 5 amino acid mixture
- rats Sixty minutes after the oral gavage, rats are anesthetized with an intraperitoneal injection of sodium pentobarbital at which time the gastrocnemius is excised, sectioned into red and white muscle samples, freeze clamped in liquid nitrogen and stored at -80° C. Muscle samples are digested and read in a liquid scintillation counter preset for simultaneous counting of [ 3 H] and [ 14 C] DPM.
- FIG. 1 there is shown a graph of the in vivo assay results of the glucose uptake measured in the red (RG) and white (WG) gastrocnemius muscles during the oral glucose tolerance test in the Sprague Dawley rats. As the graph indicates, both the RG and the WG have significantly greater glucose uptake following administration of the carbohydrate and amino acid blend as compared to the carbohydrate alone. This indicates that the amino acid blend increases the glucose uptake into the muscle cells.
- skeletal muscle glucose uptake across different fiber types isolated from Zucker obese rats is analyzed following the administration of: (1) a carbohydrate-only solution; or (2) a carbohydrate solution including a specific amino acid blend of the present disclosure.
- the carbohydrate-only solution is a 22.5% (by weight) glucose standard solution.
- the carbohydrate solution including a specific amino acid blend is a 22.5% (by weight) glucose standard solution (50 mL) including 5.28 mg of cysteine, 3.36 mg of methionine, 6.68 mg of valine, 944.8 mg of isoleucine, and 6.58 mg of leucine.
- the amino acid blend is introduced into 45 mL of the 22.5% glucose solution while stirring at high speed for about 1.5 hours. After all of the amino acids are dissolved, the solution is brought up to 50 mL.
- the amino acid blend has a molar ratio of
- isoleucine leucine : valine :methionine : cysteine of 97.65:0.68:0.77:0.31 :0.59.
- Obese Zucker rats are orally gavaged 8 ml/kg with either carbohydrate (CHO) or carbohydrate plus a 5 amino acid mixture (CHO-AA). Fifteen minutes after the gavage, a bolus containing 40 ⁇ 3 ⁇ 4 body weight 2-[l,2- 3 H] deoxyglucose ( 3 H-2-DG) and 20 ⁇ Ci/kg body weight [U- 14 C] mannitol is injected by syringe via a tail vein.
- CHO carbohydrate
- CHO-AA 5 amino acid mixture
- rats Sixty minutes after the oral gavage, rats are anesthetized with an intraperitoneal injection of sodium pentobarbital at which time the gastrocnemius and soleus muscle are excised, sectioned into red and white muscle samples (gastrocnemius muscle), freeze clamped in liquid nitrogen and stored at -80° C. Muscle samples are digested and read in a liquid scintillation counter preset for simultaneous counting of [ 3 H] and [ 14 C] DPM.
- FIGS 2 and 3 there are shown graphs of the in vivo assay results of the glucose uptake measured in the red gastrocnemius muscle and the soleus muscle during the oral glucose tolerance test in the Zucker obese rats, an animal model used for the study of insulin resistance.
- both the red gastrocnemius muscle and soleus muscle have significantly greater glucose uptake following administration of the carbohydrate and amino acid blend as compared to the carbohydrate alone. This indicates that the amino acid blend increases the glucose uptake into the different fiber types in insulin resistant muscle.
- Sprauge Dawley rats are fasted for 8 hours and then anesthetized via an intraperitoneal (IP) injection of pentobarbital sodium (65 mg/kg body weight). The epitrochlearis muscle is then surgically dissected for in vitro incubation.
- IP intraperitoneal
- the isolated muscles are individually pre-incubated for 50 min at 29 °C in 1.5 ml of continuously gassed (95%02/5%C02) Krebs-Henseliet bicarbonate (KHB) buffer containing 0.1% BSA, 32 mM mannitol, and 8 mM glucose. Following the pre-incubation, muscles are washed for 10 min at 29 °C in fresh KHB buffer (1.5 ml) containing 0.1% BSA, 2 mM pyruvate, and 38 mM mannitol.
- KHB Krebs-Henseliet bicarbonate
- muscles are then incubated for 20 min at 29 °C in the uptake mediums containing different levels of the 5 amino acids with radioactive tracers (280 ⁇ / ⁇ [ 3 H] 2-deoxyglucose and 10 ⁇ / ⁇ [ 14 C]-mannitol). Following the last incubation period, muscles are blotted and freeze clamped with Wallenberg tongs cooled in liquid nitrogen. The muscles are stored at -80 °C until analysis.
- radioactive tracers 280 ⁇ / ⁇ [ 3 H] 2-deoxyglucose and 10 ⁇ / ⁇ [ 14 C]-mannitol.
- the amino acid mixture is based on the concentration of isoleucine within the incubation medium, and the ratios of each individual amino acid in the medium are kept the same among different doses. For the concentrations of the individual amino acids, see Table 1.
- Glucose uptake in the incubated muscles is estimated by determining the incorporation rate of 3 H-labeled 2-deoxyglucose (2-DG) into the muscle fibers during the 20 minute incubation.
- Frozen muscle samples are weighed (15-25 mg) and digested in 1 ml IN KOH at 60 °C for 20 minutes. Muscle homogenate then are neutralized with 1 ml IN HC1, and the neutralized supernatant are added into 6 ml BioSafe II scintillation cocktail (Research Products International, Mt. Prospect, IL). Samples are counted for 3 H and 14 C in an LS-6000 liquid scintillation spectrophotometer (Beckman, Fullerton, CA). Muscle 2-DG uptake is calculated as the difference between total muscle 2-DG and 2-DG in the extracellular space. The amount of 2-DG contained in the extracellular space is determined and corrected by the amount of [ 14 C]-mannitol retained in the tissue.
- FIG. 4 there is shown graphs of the in vitro assay results of the glucose uptake in response to treatment of the epitrochlearis muscles with different doses of the specific amino acid blend.
- the muscle has significantly greater glucose uptake following administration of the increased doses of the amino acid blend as compared to basal levels. This indicates that the amino acid blend increases the glucose uptake into the muscle.
- glucose transport of C 2 C 12 myotubes is analyzed after treatment with various solutions, including insulin (100 nM in Krebs-Ringers-HEPES buffer with bovine serum albumin (BSA), glucose, and sodium bicarbonate (KRH-BGB), 5AA (14.4 mM isoleucine, 0.10 mM leucine, 0.11 mM valine, 0.05 mM methionine, and 0.09 mM cysteine), 4AA (0.10 mM leucine, 0.11 mM valine, 0.05 mM methionine, and 0.09 mM cysteine), ILE (14.4 mM isoleucine in KRH-BGB), and a basal treatment (KRH- BGB alone).
- insulin 100 nM in Krebs-Ringers-HEPES buffer with bovine serum albumin (BSA), glucose, and sodium bicarbonate (KRH-BGB)
- 5AA (14.4 mM isoleucine, 0.10 mM leucine
- C 2 Ci 2 myoblast plates (6-well plates) are prepared at a concentration of ⁇ 6 X 10 4 cells/well (3 ml of suspension/well). Following preparation, the C 2 Ci 2 myoblast plates are differentiated to C 2 Ci 2 myotubes by replacing the growth medium with differentiation medium (DMEM, 2% Horse Serum (HS), L ⁇ alanyi ⁇ L-glutaraine at a final concentration of 1%, and Penicillin-Streptomycin (10,000 IU/10,000 ⁇ g/ml) solution at a final concentration of 1%. Once differentiated, the C 2 Ci 2 myotubes are subjected to a C 2 Ci 2 glucose transport assay.
- DMEM Dulbecco's Modified Eagle Medium
- FBS Fetal Bovine Serum
- Penicillin-Streptomycin 10,000 IU/10,000 ⁇ g/ml
- 0.5 ml of cell extraction buffer is added to each To well and a cell scraper is used to dislodge the treated cells from the plates.
- 0.25 ml of the cell suspension is dispensed into a scintillation vial and the remaining cell suspension is dispensed into a separate tube for storage at ⁇ 20°C until protein testing (Bicinchoninic Acid (BCA)) could be completed.
- BCA Protein testing
- 15 ml of liquid scintillation fluid is added.
- the wells including the insulin control and test amino acid-containing solution samples are then processed as the T 0 wells.
- radioactive C2C12 glucose transport assay protein samples i.e., the 0.25 ml of cell extraction buffer that is not added to the scintillation vials, but is frozen and later tested for protein
- a protein standard from the BCA kit is used to prepare the standard curve by making a series of 1 :2 dilutions in cell extraction buffer (2000 ⁇ g/ml through 125 ⁇ g/ml) and a 1 : 10 dilution of the 250 ⁇ g/ml standard (25 ⁇ g/ml).
- Duplicate wells of a flat-bottom micro titer plate are loaded with 25 ⁇ of the prepared standards, blanks, and samples. Cell extraction buffer is used in the assay blank wells.
- BCA reagents which is a 50: 1 mixture of kit components A and B
- the working solution of BCA reagents is prepared. 290 ⁇ of BCA working reagent is added to each well of the microtiter plate and gently rocked to mix the samples.
- the radioactive plate(s) are safely transferred to a 37°C incubator. Once the plate cools to room temperature, a microplate reader is used to read the absorbance at 562 nm.
- the microplate reader's software program, quadratic curve is then used to evaluate the standards and calculate the ⁇ g/ml of protein for the controls and test samples from the C 2 C 12 glucose transport assay. To determine the protein concentration associated with each scintillation vial, the ⁇ g/ml of protein is divided by 4.
- Examples 5-7 illustrate nutritional liquid embodiments of the present disclosure.
- the ingredients for each exemplified composition are described in the following table. All ingredient amounts are listed as kg per 1000 kg batch of product, unless otherwise specified.
- the amino acid blend is prepared by conventional methods as a powder comprising each of the identified amino acids.
- the amino acid powder is added slowly, with agitation, to a kettle containing the specified amount of water. Once the amino acids are fully dispersed, the solution pH is reduced to 2.4 using an 80% phosphoric acid solution, and thereafter increased to 3.2 using a 45% KOH solution.
Abstract
Disclosed are compositions and methods for increasing muscle glucose uptake and decreasing muscle recovery time in an individual. The compositions useful for these methods include specific amino acid blends including isoleucine, leucine, valine, cysteine and methionine. These compositions may be used by healthy individuals and/or prediabetic or diabetic individuals to increase muscle glucose uptake and decrease muscle recovery time. Some methods of using the specific amino acids blends are directed at diabetics for controlling blood glucose levels.
Description
METHODS FOR INCREASING MUSCLE GLUCOSE UPTAKE AND DECREASING MUSCLE RECOVERY TIME USING AMINO ACID BLEND
FIELD OF THE DISCLOSURE
[0001] The present disclosure relates to methods for increasing muscle glucose uptake and decreasing muscle recovery time by administration of a composition comprising select amino acid blends.
BACKGROUND OF THE DISCLOSURE
[0002] Adult nutritional supplements are widely commercially available. Many of these supplements are directed at the healthy adult population seeking to increase muscle mass and decrease muscle recovery time after a workout. Many supplements seek to increase glucose uptake into muscle cells to speed the recovery of the muscle tissue after physical exertion.
[0003] Glucose uptake and transport into muscle cells may also be particularly important for the pre-diabetic and diabetic population, as it is well known that a decrease in muscle glucose uptake is one of the early symptoms of diabetes. By increasing the rate of glucose uptake and transport into muscle cells, pre-diabetics and diabetics can more easily maintain a steady level of blood glucose and avoid unwanted glucose spikes.
[0004] To date, the rate of glucose uptake into muscle cells has been primarily enhanced by the use of exogenous insulin, physical exertion and exercise, and/or carbohydrate loading. Although one or a combination of these options may result in an increase uptake of glucose into muscle cells and the resulting benefits, they may not be suitable for all adults. For example, hypoglycemic episodes may be associated with insulin use in some adults. Additionally, not all adults have the physical ability to perform exercise, nor the physical ability to ingest a large number of carbohydrate calories.
[0005] As such, there is a need for compositions and methods for easily and effectively increasing the uptake of glucose into muscle tissue and reduce muscle recovery time. Additionally, it would be very beneficial if the compositions and methods could be
utilized by a wide variety of adults, irrespective of overall health condition and physical ability.
SUMMARY OF THE DISCLOSURE
[0006] The present disclosure is directed to methods of increasing muscle glucose uptake and improving muscle glucose metabolism by administering a composition including a specific amino acid blend comprising isoleucine, leucine, valine, methionine, and cysteine. In some embodiments, the specific amino acid blend is utilized to increase the muscle recovery rate of an individual.
[0007] The present disclosure is specifically directed to a method of increasing glucose uptake in a muscle cell of an individual. The method comprises administering to the individual a composition comprising an amino acid blend comprising isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of about 97.65 :about 0.68:about 0.77:about 0.31 :about 0.59, respectively.
[0008] The present disclosure is further directed to a method of increasing the muscle recovery rate of an individual. The method comprises administering to the individual a composition comprising an amino acid blend comprising isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of about 97.65 :about 0.68:about
0.77:about 0.31 :about 0.59, respectively.
[0009] The present disclosure is further directed to a method of increasing the muscle glucose metabolism rate of an individual. The method comprises administering to the individual a composition comprising an amino acid blend comprising isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of about 97.65 :about 0.68:about 0.77:about 0.31 :about 0.59, respectively.
[0010] The present disclosure is further directed to a method of managing or treating diabetes or prediabetes in an individual. The method comprises administering to the individual a composition comprising an amino acid blend comprising isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of about 97.65 :about 0.68:about 0.77:about 0.31 :about 0.59, respectively.
[0011] The present disclosure is further directed to a method of managing or treating insulin resistance in an individual. The method comprises administering to the individual a composition comprising an amino acid blend comprising isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of about 97.65 :about 0.68:about
0.77:about 0.31 :about 0.59, respectively.
[0012] The present disclosure is further directed to a method of preventing or treating skeletal muscle loss in an individual. The method comprises administering to the individual a composition comprising an amino acid blend comprising isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of about 97.65 :about 0.68:about
0.77:about 0.31 :about 0.59, respectively.
[0013] The present disclosure is further directed to a method of increasing glucose uptake in a muscle cell of a diabetic athlete. The method comprises administering to the individual a composition comprising an amino acid blend comprising isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of about 97.65 :about 0.68:about 0.77:about 0.31 :about 0.59, respectively.
[0014] It has been unexpectedly found that by administering a specific amino acid blend including isoleucine, leucine, valine, methionine, and cysteine, the glucose uptake, and hence the glucose metabolism rate, in muscle cells can be increased such that the time period for muscle recovery after a trauma or physical activity, such as after a workout, is reduced. Surprisingly, the specific amino acid blend increases glucose transport into muscle cells and reduces or eliminates that need for other means of increasing glucose transport into muscle cells, such as insulin use or ingestion of large amounts of
carbohydrates.
[0015] Additionally, it has further been discovered that the specific amino acid blend is particularly useful for prediabetics and diabetics as they typically experience a significant decrease in muscle glucose metabolism as diabetes progresses. By utilizing the specific amino acid blend, these individuals can increase muscle glucose uptake, which allows them to control their blood glucose level without solely relying on insulin or methodologies that can interfere with digestion.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] Figure 1 is a graph showing the glucose uptake in red and white gastrocnemius muscles from Sprague-Dawley rats during an oral glucose tolerance test.
[0017] Figure 2 is a graph showing the glucose uptake in red gastrocnemius muscles from Zucker obese rats during an oral glucose tolerance test.
[0018] Figure 3 is a graph showing the glucose uptake in the soleus muscle from Zucker obese rats during an oral glucose tolerance test.
[0019] Figure 4 is a graph showing the glucose uptake in response to the treatment of epitrochlearis muscles from rats with different doses of a specific amino acid blend.
[0020] Figure 5 is a graph showing the C2C12 myotubular glucose transport in response to treatment with various amino acid blends.
DETAILED DESCRIPTION OF THE DISCLOSURE
[0021] The compositions and methods of the present disclosure are directed to specific blends of amino acids including isoleucine, leucine, valine, methionine, and cysteine for increasing the rate of muscle glucose uptake and metabolism. These and other essential or optional elements or limitations of the compositions and methods of the present disclosure are described in detail hereinafter.
[0022] The term "healthy individual" as used herein refers to a person who is in generally good health, and is not obese, a prediabetic or diabetic.
[0023] The term "diabetic athlete" as used herein refers to an athlete who is diabetic, prediabetic, or suffers from impaired glucose tolerance.
[0024] All percentages, parts and ratios as used herein, are by weight of the total composition, unless otherwise specified. All such weights as they pertain to listed ingredients are based on the active level and, therefore, do not include solvents or byproducts that may be included in commercially available materials, unless otherwise specified.
[0025] Numerical ranges as used herein are intended to include every number and subset of numbers within that range, whether specifically disclosed or not. Further, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 2 to 8, from 3 to 7, from 5 to 6, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.
[0026] All references to singular characteristics or limitations of the present disclosure shall include the corresponding plural characteristic or limitation, and vice versa, unless otherwise specified or clearly implied to the contrary by the context in which the reference is made.
[0027] All combinations of method or process steps as used herein can be performed in any order, unless otherwise specified or clearly implied to the contrary by the context in which the referenced combination is made.
[0028] The various embodiments of the compositions of the present disclosure may also be substantially free of any optional or selected essential ingredient or feature described herein, provided that the remaining composition still contains all of the required ingredients or features as described herein. In this context, and unless otherwise specified, the term "substantially free" means that the selected composition contains less than a functional amount of the optional ingredient, typically less than 0.1% by weight, and also including zero percent by weight of such optional or selected essential ingredient.
[0029] The compositions and corresponding methods of the present disclosure can comprise, consist of, or consist essentially of the essential elements and limitations of the disclosure as described herein, as well as any additional or optional ingredients, components, or limitations described herein or otherwise useful in the compositions or methods.
Product Form
[0030] The compositions including the specific amino acid blends useful in the methods of the present disclosure may be formulated in any known or otherwise suitable product form for oral or parenteral administration. Oral product forms are generally
preferred and include any solid, liquid, or powder formulation suitable for use herein, provided that such a formulation allows for safe and effective oral delivery of the essential and other selected ingredients from the selected product form.
[0031] Non-limiting examples of solid nutritional product forms suitable for use herein include snack and meal replacement products, including those formulated as bars, sticks, cookies or breads or cakes or other baked goods, frozen liquids, candy, breakfast cereals, powders or granulated solids or other particulates, snack chips or bites, frozen or retorted entrees and so forth.
[0032] Non-limiting examples of liquid product forms suitable for use herein include snack and meal replacement products, hot or cold beverages, carbonated or non carbonated beverages, juices or other acidified beverages, milk or soy-based beverages, shakes, coffees, teas, enteral feeding compositions, and so forth. These liquid
compositions are most typically formulated as suspensions or emulsions, but can also be formulated in any other suitable forms such as clear liquids, solutions, liquid gels, and so forth.
[0033] Other non- limiting examples of suitable oral product forms include semisolid or semi-liquid compositions (e.g., puddings, gels), as well as more conventional product forms such as capsules, tablets, caplets, pills, and so forth. The quantity of the composition for providing an effective amount of the defined amino acid blend to the targeted user may be contained in one or a plurality of individual dosage forms, e.g., in one tablet or a plurality of tablets that may be administered in single or multiple dosages per day.
[0034] For product forms such as lozenges, tablets (e.g. chewable, coated, etc.), pastes, or gels, the amino acid blend may be formulated at concentrations most typically ranging from about 5 to about 50%, including from about 15 to about 33%, and also including from about 15 to about 25%, by weight of the product form, all in combination with excipients or other ingredients such as carbohydrates, acidulants, flavors, and colors.
Amino Acid Blend
[0035] The compositions useful in the methods of the present disclosure comprise a select blend of branched chain amino acids and sulfur-containing amino acids, the former of which includes valine (VAL), leucine (LEU), and isoleucine (ILE), and the latter of which includes cysteine (CYS) and methionine (MET). The compositions include a specific amino acid blend of at least isoleucine, leucine, valine, cysteine, and methionine, the quantity or amount of which should be sufficient to provide an increase in glucose uptake in a muscle cell of an individual, an increase in the muscle recovery rate of an individual, and/or an increase in muscle glucose metabolism rate in an individual upon administration.
[0036] Generally, the amino acid blend is present in the composition in an amount sufficient to provide an individual with from about 0.1 grams to about 50 grams per day, desirably from about 1 gram to about 15 grams per day of the amino acid blend. The composition may be administered once, twice, three times or more daily to reach the desired level of amino acid blend intake per day.
[0037] In one embodiment, the amino acid blend comprises isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of about 97.65 :about 0.68:about
0.77:about 0.31 :about 0.59, respectively. In another embodiment, the amino acid blend comprises isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of 96.49- 98.00:0.65-0.70:0.68-0.81 :0.26-0.38:0.55-0.62, respectively.
[0038] In another embodiment of the present disclosure, the composition contains from about 1.0 to about 200 mg/kg of body weight of isoleucine; from about 0.001 to about 10 mg/kg of body weight of leucine; from about 0.001 to about 10 mg/kg of body weight of valine; from about 0.001 to about 10 mg/kg of body weight of cysteine; and from about 0.001 to about 10 mg/kg of body weight of methionine. Body weight refers to body weight of the individual or subject patient to which the composition is administered.
[0039] In another embodiment of the present disclosure, the composition contains from about 120 to about 180 mg/kg of body weight of isoleucine; from about 0.25 to about 7.5 mg/kg of body weight of leucine; from about 0.25 to about 7.5 mg/kg of body weight of
valine; from about 0.25 to about 7.5 mg/kg of body weight of cysteine; and from about 0.2 to about 5 mg/kg of body weight of methionine.
[0040] In another embodiment of the present disclosure, the composition contains from about 130 to about 170 mg/kg of body weight of isoleucine; from about 0.5 to about 5 mg/kg of body weight of leucine; from about 0.5 to about 5 mg/kg of body weight of valine; from about 0.5 to about 5 mg/kg of body weight of cysteine; and from about 0.3 to about 3 mg/kg of body weight of methionine.
[0041] In some embodiments, the amount of amino acids for use in the select amino acid blends may also be characterized as a weight ratio of the branched chain to sulfur-containing amino acids of at least about 10: 1 , including at least about 50: 1 , and also including at least about 100: 1 , and also including from 500: 1 to 10: 1.
[0042] The individual amino acids for use in the compositions and methods of the present disclosure can be provided in the form of natural, intact or hydrolyzed proteins, which may therefore include free amino acids as well as various polypeptides or intact proteins within the compositions or otherwise consumed as part of the methods, provided that such sources provide the requisite kind and amount of amino acids in the blends as described herein.
[0043] The amino acid blends for use in the methods and composition may therefore comprise from 0 to 100% , including from 50 to 100%, also including from 75 to 95%), also including from 90 to 100%, and also including 100%, on a molar or weight basis of the targeted amino acid blend in the form of free amino acids within the compositions or otherwise administered in the methods. The amino acid blends may also be provided in the form of a blend of one or more of free amino acids, intact proteins, and hydrolyzed proteins or other protein fractions.
[0044] The amino acids in the defined blend may be in the L or R configuration, or a mixture thereof, although most amino acids for use in the formulation will typically be in the L configuration. Suitable amino acids described herein are commercially available from a number of different material suppliers, including Sigma- Aldrich Corporation (St. Louis, Missouri.)
[0045] When a composition of the present disclosure is in liquid form, most typically as an oral liquid or beverage, or after a powder embodiment is reconstituted to form an oral liquid composition, the pH of the liquid composition is suitable for appropriate administration to a subject, such as by oral administration. In one such liquid embodiment, the composition has a pH of from about 2.5 to about 8.0, including from about 2.7 to about 7.0, and also including from about 3.0 to about 5.5, and also including from about 3.0 to about 5.0.
[0046] The compositions of the present disclosure may further comprise one or more supplemental amino acids, non-limiting examples of which include aspartic acid (ASP), threonine (THR), serine (SER), glutamic acid (GLU), proline (PRO), glycine (GLY), alanine (ALA), tyrosine (TYR), histidine (HIS), lysine (LYS), arginine (ARG), tryptophan (TRY), phenylalanine (PHE), and combinations thereof. The compositions may contain a sufficient amount of one or more (such as at least about 2 or more, and at least about 5 or more) supplemental amino acids to contribute to providing a treatment for at least one of impaired glucose tolerance and diabetes.
[0047] In one embodiment of the present disclosure, the composition contains one or more of from about 0.01 to about 30 mg/kg (including from about 1 to about 30 mg/kg and also including from about 5 to about 20 mg/kg) of body weight of each of aspartic acid and glutamic acid; from about 0.001 to about 10 mg/kg (including from about 0.1 to about 10 mg/kg and also including from about 0.5 to about 5 mg/kg) of body weight of each of threonine, serine, proline, histidine, and lysine; and from about 0.001 to about 20 mg/kg (including from about 0.1 to about 20 mg/kg and also including from about 1 to about 10 mg/kg) of body weight of each of glycine, alanine, tyrosine, arginine, and tryptophan.
[0048] In some instances, the compositions of the present disclosure contain little or no phenylalanine. For example, the composition may contain less than about 10 mg/kg of body weight of phenylalanine or less than about 5% by weight. In another embodiment, the composition contains less than about 5 mg/kg of body weight of phenylalanine. In yet another embodiment, the composition contains zero or less than about 1 mg/kg of body weight of phenylalanine.
Macronutrients
[0049] The compositions of the present disclosure including the amino acid blend may further comprise one or more other macronutrients including a fat source, a carbohydrate source, and a protein source, all in addition to the amino acid blend as described herein.
[0050] The optional macronutrients in combination with the other essential or added ingredients may provide up to about 1000 kcal of energy per serving or dose, including from about 25 kcal to about 900 kcal, also including from about 75 kcal to about 700 kcal, also including from about 100 kcal to about 500 kcal, also including from about 150 kcal to about 400 kcal, and also including from about 200 kcal to about 300 kcal, per serving or dose, most suitably as a single, undivided serving or dose.
[0051] Many different sources and types of proteins, lipids, and carbohydrates are known and can be used in the various products described herein, provided that the selected nutrients are safe and effective for oral administration and are compatible with the essential and other added ingredients.
[0052] Carbohydrates suitable for use in the compositions of the present disclosure may be simple, complex, or variations or combinations thereof. Non-limiting examples of suitable carbohydrates include hydrolyzed or modified starch or cornstarch, maltodextrin, glucose polymers, sucrose, corn syrup, corn syrup solids, rice-derived carbohydrate, glucose, fructose, lactose, high fructose corn syrup, indigestible
oligosaccharides (e.g., fructooligosaccharides), soluble or insoluble fiber, honey, sugar alcohols (e.g., maltitol, erythritol, sorbitol), and combinations thereof.
[0053] Proteins suitable for use in the compositions, in addition to the amino acid blend component as described herein, include hydrolyzed, partially hydrolyzed or non- hydrolyzed proteins or protein sources, and can be derived from any known or otherwise suitable source such as milk (e.g., casein, whey), animal (e.g., meat, fish), cereal (e.g., rice, corn), vegetable (e.g., soy), or combinations thereof.
[0054] Fats suitable for use in the compositions include coconut oil, fractionated coconut oil, soy oil, corn oil, olive oil, safflower oil, high oleic safflower oil, MCT oil (medium chain triglycerides), sunflower oil, high oleic sunflower oil, palm and palm kernel oils, palm olein, canola oil, marine oils, cottonseed oils, structured lipids, and combinations thereof.
[0055] The concentration or amount of fat, protein, and carbohydrate in the compositions of the present disclosure may vary considerably depending upon the particular product form (e.g., solid, liquid, powder) and the various other formulations and targeted dietary needs. These macronutrients are most typically formulated within any of the caloric ranges (embodiments A-D) described in the following table.
Each numerical value is preceded by the term "about"
Other Optional Ingredients
[0056] The compositions including the amino acid blend of the present disclosure may further comprise other optional components that may modify the physical, chemical, aesthetic or processing characteristics of the products or serve as pharmaceutical or additional nutritional components when used in the targeted population. Many such optional ingredients are known or otherwise suitable for use in medical food or other nutritional products or pharmaceutical dosage forms and may also be used in the compositions herein, provided that such optional ingredients are safe for oral
administration and are compatible with the essential and other ingredients in the selected product form.
[0057] Non-limiting examples of such optional ingredients include fibers, preservatives, anti-oxidants, emulsifying agents, buffers, pharmaceutical actives, additional nutrients as described herein, colorants, flavorants, thickening agents and stabilizers, emulsifying agents, lubricants, sweetening agents, vitamins, minerals and so forth.
Methods of Manufacture
[0058] The compositions including the specific amino acid blends of the present disclosure may be prepared by any known or otherwise effective manufacturing technique for preparing the selected product form. Many such techniques are known for any given product form such as nutritional liquids or nutritional bars and can easily be applied by one of ordinary skill in the art to the nutritional products described herein.
[0059] The compositions can likewise be prepared by any known or otherwise effective manufacturing technique for preparing the various pharmaceutical product forms. Many such techniques are known for any given pharmaceutical product form such as capsules, tablets, liquids, and so forth, and can easily be applied by one of ordinary skill in the art to the compositions described herein.
[0060] As a basic liquid formulation, the compositions may be prepared by dissolving each of the selected amino acids in water or a dilute acid solution, and then combining the different amino acid solutions to form a liquid embodiment of the present disclosure.
[0061] As a basic solid formulation, the compositions may be prepared by combining the different powder forms of the selected amino acids, along with any tablet forming materials or other excipients, and then dry blending the powders prior to processing it into the desired solid product form, e.g., tablet, capsule, caplet, and so forth.
[0062] In yet another embodiment, the compositions may be formulated as a nutritional liquid, including a juice or milk or soy-based liquid, comprising the selected amino acid blend. Such an embodiment may be prepared by first forming an oil and fiber blend containing all formulation oils, any emulsifier, fiber and fat-soluble vitamins.
Additional slurries (typically a carbohydrate and two protein slurries) are prepared separately by mixing the carbohydrate and minerals together and the protein in water. The
slurries are then mixed together with the oil blend. The resulting mixture is homogenized, heat processed, standardized with any water-soluble vitamins, flavored and the liquid terminally sterilized or aseptically filled or dried to produce a powder.
[0063] Other product forms such as nutritional bars may be manufactured, for example, using cold extrusion technology as is known and commonly described in the bar manufacturing art. To prepare such compositions, typically all of the powdered
components are dry blended together, which typically includes the amino acid blend and any proteins, vitamin premixes, certain carbohydrates, and so forth. The fat-soluble components are then blended together and mixed with any powdered premixes. Finally any liquid components are then mixed into the composition, forming a plastic like composition or dough. The resulting plastic mass can then be shaped, without further physical or chemical changes occurring, by cold forming or extrusion, wherein the plastic mass is forced at relatively low pressure through a die, which confers the desired shape. The resultant exudate is then cut off at an appropriate position to give products of the desired weight. If desired the solid product is then coated, to enhance palatability, and packaged for distribution.
[0064] The solid nutritional embodiments of the present invention may also be manufactured through a baked application or heated extrusion to produce solid product forms such as cereals, cookies, crackers, and similar other product forms. One
knowledgeable in the nutrition manufacturing arts is able to select one of the many known or otherwise available manufacturing processes to produce the desired final product.
[0065] The compositions may, of course, be manufactured by other known or otherwise suitable techniques not specifically described herein without departing from the spirit and scope of the present invention. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive and all changes and equivalents also come within the description of the present invention.
Methods of Use
[0066] The compositions including the specific amino acid blend as described herein may be administered to individuals to increase the rate of glucose uptake in a muscle cell of the individual, to increase the rate of muscle recovery rate of an individual, to
increase the rate of muscle glucose metabolism in an individual, or to increase the fuel supply to the muscles of an individual. The individual may be a healthy individual, such as an athlete, who wants to speed muscle recovery after a trauma or physical exertion.
Alternatively, the individual may be an individual who is a prediabetic or has diabetes, has insulin resistance, or impaired glucose tolerance, or who wants to control and maintain safe blood glucose levels with the use of little or no insulin. Alternatively the individual may be an individual who suffers from skeletal muscle loss, cancer cachexia, sarcopenia,
HIV/AIDS, COPD, or a combination thereof.
[0067] The compositions and methods of the present disclosure may be directed to any individual, including humans and other mammals such dogs, cats, rodents, cows, sheep, swine, goats, horses and other hoofed animals, and so forth. Healthy individuals at risk of type 2 diabetes may be administered the compositions as well.
[0068] The compositions including the specific amino acid blend may be administered before, during, or after carbohydrate intake (such as from a meal, drink, or snack), or before, during or after exercise to increase the rate of muscle recovery and/or increase muscle glucose metabolism rates. In one embodiment, the administration of the amino acid composition is conducted within about one hour of carbohydrate consumption and/or physical exertion by the subject. In another embodiment, the administration of the amino acid composition is conducted within about 30 minutes of carbohydrate
consumption and/or exertion by the subject.
[0069] The compositions including the specific amino acid blend may be used to increase muscle uptake of blood glucose to treat and/or manage glucose tolerance, diabetes, obesity, skeletal muscle loss, sarcopenia, muscle wasting diseases, cachexia due to cancer, HIV/ AIDS, COPD and combinations thereof, and/or symptoms and side effects thereof. Specifically, the compositions and methods may be used to treat type 1 diabetes, type 2 diabetes and/or symptoms thereof. Symptoms and side effects of diabetes include one or more of high blood glucose levels, sleep habits such as insomnia, general energy level such as lethargy, decreased strength, body weight/poor or increased appetite, reflux, irregularity, stomach neuropathy, kidney failure, heart disease, stroke, and deteriorating eyesight.
[0070] The methods of the present disclosure as described herein are also intended to include the use of such methods in individuals unaffected by or not otherwise afflicted with glucose intolerance, diabetes, obesity, sarcopenia, muscle wasting diseases, etc., for the purpose of managing, preventing, minimizing, or delaying the development of such diseases or conditions over time. For such prevention purposes, the methods of the present disclosure preferably include continuous, daily administration of the compositions as described herein. Such preventive methods may be directed at adults or others who are at risk of developing muscle wasting and/or diabetes.
[0071] In one aspect of the invention, administration of the compositions of the subject invention to a subject in need thereof after, during, or before carbohydrate ingestion increases muscle glucose metabolism. Blood glucose levels may be determined using whole blood, blood plasma or blood serum. Unless otherwise indicated, blood glucose levels refer to analysis of whole blood. Administration of the compositions decreases blood glucose levels after carbohydrate ingestion (compared to blood glucose levels after carbohydrate ingestion without administration of the amino acid compositions) in at least one of about 30 minutes after carbohydrate intake, about 60 minutes after carbohydrate intake, about 90 minutes after carbohydrate intake, and about 120 minutes after
carbohydrate intake.
EXAMPLES
[0072] The following examples illustrate specific embodiments and/or features of the compositions and methods of the present disclosure. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the present disclosure, as many variations thereof are possible without departing from the spirit and scope of the disclosure. All exemplified amounts are weight percentages based upon the total weight of the formulation, unless otherwise specified.
Example 1
[0073] In this Example, the rate of glucose uptake in red gastrocnemius and white gastrocnemius muscles of Sprague-Dawley rats is analyzed following the administration of: (1) a carbohydrate-only solution; or (2) a carbohydrate solution including a specific amino acid blend of the present disclosure.
[0074] The carbohydrate-only solution administered is a 22.5% (by weight) glucose standard solution. The carbohydrate solution including a specific amino acid blend is a 22.5%) (by weight) glucose standard solution (50 mL) including 5.28 mg of cysteine, 3.36 mg of methionine, 6.68 mg of valine, 944.8 mg of isoleucine, and 6.58 mg of leucine. The amino acid blend is introduced into 45 mL of the 22.5% glucose solution while stirring at high speed for about 1.5 hours. After all of the amino acids are dissolved, the solution is brought up to 50 mL. The amino acid blend has a molar ratio of
isoleucine: leucine : valine methionine: cysteine of about 97.65:0.68:0.77:0.31 :0.59.
[0075] Sprauge Dawley rats are orally gavaged 8 ml/kg with either carbohydrate (CHO) or carbohydrate plus the 5 amino acid mixture (CHO-AA). Fifteen minutes after the gavage, a bolus containing 40 μΟΔ¾ body weight 2-[l,2-3H] deoxyglucose (3H-2-DG) and 20 μΟΔ¾ body weight [U-14C] mannitol is injected by syringe via a tail vein. Sixty minutes after the oral gavage, rats are anesthetized with an intraperitoneal injection of sodium pentobarbital at which time the gastrocnemius is excised, sectioned into red and white muscle samples, freeze clamped in liquid nitrogen and stored at -80° C. Muscle samples are digested and read in a liquid scintillation counter preset for simultaneous counting of [3H] and [14C] DPM.
[0076] Referring now to Figure 1 , there is shown a graph of the in vivo assay results of the glucose uptake measured in the red (RG) and white (WG) gastrocnemius muscles during the oral glucose tolerance test in the Sprague Dawley rats. As the graph indicates, both the RG and the WG have significantly greater glucose uptake following administration of the carbohydrate and amino acid blend as compared to the carbohydrate alone. This indicates that the amino acid blend increases the glucose uptake into the muscle cells.
Example 2
[0077] In this Example, skeletal muscle glucose uptake across different fiber types isolated from Zucker obese rats is analyzed following the administration of: (1) a carbohydrate-only solution; or (2) a carbohydrate solution including a specific amino acid blend of the present disclosure.
[0078] The carbohydrate-only solution is a 22.5% (by weight) glucose standard solution. The carbohydrate solution including a specific amino acid blend is a 22.5% (by weight) glucose standard solution (50 mL) including 5.28 mg of cysteine, 3.36 mg of methionine, 6.68 mg of valine, 944.8 mg of isoleucine, and 6.58 mg of leucine. The amino acid blend is introduced into 45 mL of the 22.5% glucose solution while stirring at high speed for about 1.5 hours. After all of the amino acids are dissolved, the solution is brought up to 50 mL. The amino acid blend has a molar ratio of
isoleucine : leucine : valine :methionine : cysteine of 97.65:0.68:0.77:0.31 :0.59.
[0079] Obese Zucker rats are orally gavaged 8 ml/kg with either carbohydrate (CHO) or carbohydrate plus a 5 amino acid mixture (CHO-AA). Fifteen minutes after the gavage, a bolus containing 40 μΟΔ¾ body weight 2-[l,2-3H] deoxyglucose (3H-2-DG) and 20 μCi/kg body weight [U-14C] mannitol is injected by syringe via a tail vein. Sixty minutes after the oral gavage, rats are anesthetized with an intraperitoneal injection of sodium pentobarbital at which time the gastrocnemius and soleus muscle are excised, sectioned into red and white muscle samples (gastrocnemius muscle), freeze clamped in liquid nitrogen and stored at -80° C. Muscle samples are digested and read in a liquid scintillation counter preset for simultaneous counting of [3H] and [14C] DPM.
[0080] Referring now to Figures 2 and 3, there are shown graphs of the in vivo assay results of the glucose uptake measured in the red gastrocnemius muscle and the soleus muscle during the oral glucose tolerance test in the Zucker obese rats, an animal model used for the study of insulin resistance. As the graphs indicate, both the red gastrocnemius muscle and soleus muscle have significantly greater glucose uptake following administration of the carbohydrate and amino acid blend as compared to the carbohydrate alone. This indicates that the amino acid blend increases the glucose uptake into the different fiber types in insulin resistant muscle.
Example 3
[0081] In this Example, in a specific amino acid blend experiment, the rate of glucose uptake in isolated rat epitrochlearis muscle is analyzed following the
administration of various doses of a specific amino acid blend. The rate of glucose uptake is measured at basal level (no amino acid blend), 0.5 times amino acid blend, 1 times amino acid blend, 2 times amino acid blend, and 4 times amino acid blend.
[0082] Sprauge Dawley rats are fasted for 8 hours and then anesthetized via an intraperitoneal (IP) injection of pentobarbital sodium (65 mg/kg body weight). The epitrochlearis muscle is then surgically dissected for in vitro incubation. The isolated muscles are individually pre-incubated for 50 min at 29 °C in 1.5 ml of continuously gassed (95%02/5%C02) Krebs-Henseliet bicarbonate (KHB) buffer containing 0.1% BSA, 32 mM mannitol, and 8 mM glucose. Following the pre-incubation, muscles are washed for 10 min at 29 °C in fresh KHB buffer (1.5 ml) containing 0.1% BSA, 2 mM pyruvate, and 38 mM mannitol. For measurement of glucose uptake, muscles are then incubated for 20 min at 29 °C in the uptake mediums containing different levels of the 5 amino acids with radioactive tracers (280 μθ/ητιηοΐ [3H] 2-deoxyglucose and 10 μθ/ιηιηοΐ [14C]-mannitol). Following the last incubation period, muscles are blotted and freeze clamped with Wallenberg tongs cooled in liquid nitrogen. The muscles are stored at -80 °C until analysis.
[0083] To determine the dose-response relationship, the amino acid mixture is based on the concentration of isoleucine within the incubation medium, and the ratios of each individual amino acid in the medium are kept the same among different doses. For the concentrations of the individual amino acids, see Table 1.
Table 1. The concentrations of individual amino acids in different amino acid mixtures
[0084] Glucose uptake in the incubated muscles is estimated by determining the incorporation rate of 3H-labeled 2-deoxyglucose (2-DG) into the muscle fibers during the 20 minute incubation. Frozen muscle samples are weighed (15-25 mg) and digested in 1 ml IN KOH at 60 °C for 20 minutes. Muscle homogenate then are neutralized with 1 ml IN HC1, and the neutralized supernatant are added into 6 ml BioSafe II scintillation cocktail (Research Products International, Mt. Prospect, IL). Samples are counted for 3H and 14C in an LS-6000 liquid scintillation spectrophotometer (Beckman, Fullerton, CA). Muscle 2-DG uptake is calculated as the difference between total muscle 2-DG and 2-DG
in the extracellular space. The amount of 2-DG contained in the extracellular space is determined and corrected by the amount of [14C]-mannitol retained in the tissue.
[0085] Referring now to Figure 4, there is shown graphs of the in vitro assay results of the glucose uptake in response to treatment of the epitrochlearis muscles with different doses of the specific amino acid blend. As the graph indicates, the muscle has significantly greater glucose uptake following administration of the increased doses of the amino acid blend as compared to basal levels. This indicates that the amino acid blend increases the glucose uptake into the muscle.
Example 4
[0086] In this Example, glucose transport of C2C12 myotubes is analyzed after treatment with various solutions, including insulin (100 nM in Krebs-Ringers-HEPES buffer with bovine serum albumin (BSA), glucose, and sodium bicarbonate (KRH-BGB), 5AA (14.4 mM isoleucine, 0.10 mM leucine, 0.11 mM valine, 0.05 mM methionine, and 0.09 mM cysteine), 4AA (0.10 mM leucine, 0.11 mM valine, 0.05 mM methionine, and 0.09 mM cysteine), ILE (14.4 mM isoleucine in KRH-BGB), and a basal treatment (KRH- BGB alone).
[0087] Initially, C2Ci2 myoblasts are passed in a medium consisting of
Dulbecco's Modified Eagle Medium (DMEM), 8% Fetal Bovine Serum (FBS), and Penicillin-Streptomycin (10,000 IU/10,000 μg/ml) solution at a final concentration of 1%. C2Ci2 myoblast plates (6-well plates) are prepared at a concentration of ~6 X 104 cells/well (3 ml of suspension/well). Following preparation, the C2Ci2 myoblast plates are differentiated to C2Ci2 myotubes by replacing the growth medium with differentiation medium (DMEM, 2% Horse Serum (HS), L~alanyi~L-glutaraine at a final concentration of 1%, and Penicillin-Streptomycin (10,000 IU/10,000 μg/ml) solution at a final concentration of 1%. Once differentiated, the C2Ci2 myotubes are subjected to a C2Ci2 glucose transport assay.
[0088] To begin the assay, microscopic observations of several wells of the test plates including differentiated C2Ci2 myotubes are recorded. The differentiated C2Ci2 myotubes are then washed three times (1 ml/well) with ~37°C KRH-BGB buffer and incubated for 2 hours at 37°C/5% C02 to starve the myotubes. The KRH-BGB buffer is
removed from the starved myotubes and replaced with either fresh KRH-BGB (To
(background) and Basal wells), with insulin (positive control), or with a 5AA, 4AA, or ILE test solution.
[0089] Next, 0.5 ml of 3H-deoxyglucose at 1 μθ/πύ suspended in KRH-BGB buffer is added to each well and incubated for 20 minutes at room temperature. While the test plate wells are incubated, the two T0 wells are processed to determine the background disintegrations per minute (DPM) values for the experiment. The 3H-deoxyglucose is added and immediately aspirated from each well. The test plates are placed on ice and the T0 wells are washed three times with ice cold PBS.
[0090] 0.5 ml of cell extraction buffer is added to each To well and a cell scraper is used to dislodge the treated cells from the plates. 0.25 ml of the cell suspension is dispensed into a scintillation vial and the remaining cell suspension is dispensed into a separate tube for storage at < 20°C until protein testing (Bicinchoninic Acid (BCA)) could be completed. To each scintillation vial, 15 ml of liquid scintillation fluid is added. At end of incubation, the wells including the insulin control and test amino acid-containing solution samples are then processed as the T0 wells.
[0091] All of the scintillation vials are analyzed using a liquid scintillation counter to determine DPM for each test vial, a liquid scintillation fluid blank, a cell extraction buffer (0.25 ml) control, and a radioactive control (0.10 ml of the 3H- deoxyglucose at 1 μθ/ιηΐ solution). The average time zero (T0) DPM is subtracted from the average Basal and sample DPM values. The average DPM^g protein in 0.25 ml of cell suspension is calculated after the BCA protein analysis, described below, is completed. Further, the percent of Basal results for each control and test sample is then calculated ((Sample or Control DPM per μg protein/Basal DPM per μg protein) x 100). The results are shown in Figure 5.
[0092] To conduct the BCA protein analysis, radioactive C2C12 glucose transport assay protein samples (i.e., the 0.25 ml of cell extraction buffer that is not added to the scintillation vials, but is frozen and later tested for protein) are thawed on ice. A protein standard from the BCA kit is used to prepare the standard curve by making a series of 1 :2 dilutions in cell extraction buffer (2000 μg/ml through 125 μg/ml) and a 1 : 10 dilution of the 250 μg/ml standard (25 μg/ml). Duplicate wells of a flat-bottom micro titer plate are
loaded with 25 μΐ of the prepared standards, blanks, and samples. Cell extraction buffer is used in the assay blank wells.
[0093] The working solution of BCA reagents, which is a 50: 1 mixture of kit components A and B, is prepared. 290 μΐ of BCA working reagent is added to each well of the microtiter plate and gently rocked to mix the samples. The radioactive plate(s) are safely transferred to a 37°C incubator. Once the plate cools to room temperature, a microplate reader is used to read the absorbance at 562 nm. The microplate reader's software program, quadratic curve, is then used to evaluate the standards and calculate the μg/ml of protein for the controls and test samples from the C2C12 glucose transport assay. To determine the protein concentration associated with each scintillation vial, the μg/ml of protein is divided by 4.
[0094] Referring now to Figure 5, it is shown that the average percent of basal glucose transport of myotubes treated with 5AA showed a stimulation of 15.2%, which is greater than the stimulation by 4AA alone (-1.4%) or by ILE alone (3.6%) and is greater than the expected stimulation from the sum (2.2%). Thus, the 5AA provides a synergistic effect..
Example 5-7
[0095] Examples 5-7 illustrate nutritional liquid embodiments of the present disclosure. The ingredients for each exemplified composition are described in the following table. All ingredient amounts are listed as kg per 1000 kg batch of product, unless otherwise specified.
Ingredient Example 5 (kg) Example 6 (kg) Example 7 (kg)
Water Q.S. Q.S. Q.S.
Phosphoric acid (80%) 27.49 27.49 27.49
45% KOH 8.247 8.247 8.247
Citric acid 0.2749 0.2749 0.2749
Eridex (Erythritol) 23.37 23.37 23.37
Maltitol powder 12.37 12.37 12.37
Acesulfame K (10% 0.5910 0.5910 0.5910
solution)
Sucralose liquid (25% 0.5910 0.5910 0.5910
solution)
Isoleucine 16.62 8.31 33.24
Cystine 2HCL 0.3111 0.156 0.622
Methionine 0.05910 0.03 0.118
Valine 0.1182 0.059 0.236
Leucine 0.1155 0.058 0.231
Flavor 0.6873 0.6873 0.6873
Flavor 0.5154 0.5154 0.5154
Flavor 0.5154 0.5154 0.5154
Isoleucine, cystine, methionine, valine, leucine are part of the amino acid blend
[0096] Each of the exemplified embodiments of the present invention as referenced in the preceding table may be prepared, for example, in accordance with the following batching and processing instructions.
[0097] The amino acid blend is prepared by conventional methods as a powder comprising each of the identified amino acids. The amino acid powder is added slowly, with agitation, to a kettle containing the specified amount of water. Once the amino acids are fully dispersed, the solution pH is reduced to 2.4 using an 80% phosphoric acid solution, and thereafter increased to 3.2 using a 45% KOH solution.
[0098] To the pH-adjusted blend, the specified amounts of the premix flavor blend, citric acid, erythritol, powdered maltitol, 10%> Acesulfame potassium solution, and liquid sucralose, are added and allowed to mix thoroughly. The resulting mixture is then subjected to minimal homogenization pressure, UHT (ultra high temperature) processing at 104°C for 5 seconds, and then hot aseptic filling into suitable containers at a temperature of 88-99°C. The pH of the final product is approximately 3.2.
Claims
1. A method of increasing glucose uptake in a muscle cell of an individual, the method comprising administering to the individual a composition comprising an amino acid blend comprising isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of about 97.65:about 0.68:about 0.77:about 0.31 :about 0.59, respectively.
2. The method of claim 1 wherein the composition comprises from about 1 to about 200 mg/kg of body weight of isoleucine, from about 0.001 to about 10 mg/kg of body weight of leucine, from about 0.001 to about 10 mg/kg of body weight of valine, from about 0.001 to about 10 mg/kg of body weight of cysteine, and from about 0.001 to about 10 mg/kg of body weight of methionine.
3. The method of claim 1 wherein the composition further comprises at least one further component selected from the group consisting of from about 0.01 to about 30 mg/kg of body weight of aspartic acid, from about 0.001 to about 10 mg/kg of body weight of threonine, from about 0.001 to about 10 mg/kg of body weight of serine, from about 0.01 to about 30 mg/kg of body weight of glutamic acid, from about 0.001 to about 10 mg/kg of body weight of proline, from about 0.001 to about 20 mg/kg of body weight of glycine, from about 0.001 to about 20 mg/kg of body weight of alanine, from about 0.001 to about 20 mg/kg of body weight tyrosine, from about 0.001 to about 10 mg/kg of body weight histidine, from about 0.001 to about 10 mg/kg of body weight lysine, from about 0.001 to about 20 mg/kg of body weight of arginine, from about 0.001 to about 20 mg/kg of body weight of tryptophan, and combinations thereof.
4. The method of claim 1 wherein the composition comprises less than about 10 mg/kg of body weight phenylalanine.
5. The method of claim 1 wherein from 50 to 100% by weight of the amino acids on a molar basis are provided as free amino acids..
6. The method of claim 1 wherein the individual is administered from about 0.1 grams to about 50 grams of the amino acid blend per day.
7. The method of claim 1 wherein the individual is administered from about 1 gram to about 15 grams of the amino acid blend per day.
8. The method of claim 1 wherein the individual is a healthy individual.
9. The method of claim 1 wherein the isoleucine, leucine, valine, methionine and cysteine are present in a ratio of 97.65:0.68:0.77:0.31 :0.59, respectively.
10. A method of increasing the muscle recovery rate of an individual, the method comprising administering to the individual a composition comprising an amino acid blend comprising isoleucine, leucine, valine, methionine, and cysteine in a molar ratio of about 97.65:about 0.68:about 0.77:about 0.31 :about 0.59, respectively.
11. The method of claim 10 wherein the composition comprises from about 1 to about 200 mg/kg of body weight of isoleucine, from about 0.001 to about 10 mg/kg of body weight of leucine, from about 0.001 to about 10 mg/kg of body weight of valine, from about 0.001 to about 10 mg/kg of body weight of cysteine, and from about 0.001 to about 10 mg/kg of body weight of methionine.
12. The method of claim 10 wherein the composition further comprises at least one further component selected from the group consisting of from about 0.01 to about 30 mg/kg of body weight of aspartic acid, from about 0.001 to about 10 mg/kg of body weight of threonine, from about 0.001 to about 10 mg/kg of body weight of serine, from about 0.01 to about 30 mg/kg of body weight of glutamic acid, from about 0.001 to about 10 mg/kg of body weight of proline, from about 0.001 to about 20 mg/kg of body weight of glycine, from about 0.001 to about 20 mg/kg of body weight of alanine, from about 0.001 to about 20 mg/kg of body weight tyrosine, from about 0.001 to about 10 mg/kg of body weight histidine, from about 0.001 to about 10 mg/kg of body weight lysine, from about 0.001 to about 20 mg/kg of body weight of arginine, from about 0.001 to about 20 mg/kg of body weight of tryptophan, and combinations thereof.
13. The method of claim 10 wherein the composition comprises less than about 10 mg/kg of body weight phenylalanine.
14. The method of claim 10 wherein the composition further comprises at least one further component selected from the group consisting of vitamins, minerals, fibers, flavorants, protein, carbohydrate and fat.
15. The method of claim 10 wherein the individual is administered from about s to about 50 grams of the amino acid blend per day.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39022710P | 2010-10-06 | 2010-10-06 | |
US61/390,227 | 2010-10-06 | ||
US39265810P | 2010-10-13 | 2010-10-13 | |
US61/392,658 | 2010-10-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012047800A1 true WO2012047800A1 (en) | 2012-04-12 |
Family
ID=44910286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/054592 WO2012047800A1 (en) | 2010-10-06 | 2011-10-03 | Methods for increasing muscle glucose uptake and decreasing muscle recovery time using amino acid blend |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012047800A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
WO2015191533A1 (en) * | 2014-06-13 | 2015-12-17 | East Carolina University | Methods of using carnosinol and analogs thereof |
US9233204B2 (en) | 2014-01-31 | 2016-01-12 | Aseko, Inc. | Insulin management |
US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
US9886556B2 (en) | 2015-08-20 | 2018-02-06 | Aseko, Inc. | Diabetes management therapy advisor |
US9892234B2 (en) | 2014-10-27 | 2018-02-13 | Aseko, Inc. | Subcutaneous outpatient management |
US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
CN108471781A (en) * | 2015-12-17 | 2018-08-31 | 马斯公司 | Reduce the food product and its method of muscle breakdown |
US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
WO2021178860A1 (en) * | 2020-03-06 | 2021-09-10 | Axcella Health Inc. | Amino acid compositions and methods for muscle and myotube modulation |
US20210393593A1 (en) * | 2018-09-27 | 2021-12-23 | Societe Des Produits Nestle S.A. | Use of histidine, glycine and other amino acids for preventing insulin resistance and/or diabetes |
US11547125B2 (en) | 2015-02-13 | 2023-01-10 | Mars, Incorporated | Pet food feeding system |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005021596A2 (en) * | 2003-08-28 | 2005-03-10 | Technical Sourcing International, Inc. | Compositions and methods for glycogen synthesis |
US20050226948A1 (en) * | 2004-03-02 | 2005-10-13 | Lee Steve S | Methods for enhancing the transport of glucose into muscle |
US20070225348A1 (en) * | 2005-03-21 | 2007-09-27 | Neile Edens | Amino acid composition for improving glucose tolerance |
-
2011
- 2011-10-03 WO PCT/US2011/054592 patent/WO2012047800A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005021596A2 (en) * | 2003-08-28 | 2005-03-10 | Technical Sourcing International, Inc. | Compositions and methods for glycogen synthesis |
US20050226948A1 (en) * | 2004-03-02 | 2005-10-13 | Lee Steve S | Methods for enhancing the transport of glucose into muscle |
US20070225348A1 (en) * | 2005-03-21 | 2007-09-27 | Neile Edens | Amino acid composition for improving glucose tolerance |
Non-Patent Citations (4)
Title |
---|
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; July 2011 (2011-07-01), KLEINERT MAXIMILIAN ET AL: "An amino acid mixture enhances insulin-stimulated glucose uptake in isolated rat epitrochlearis muscle", XP002665730, Database accession no. PREV201100506587 * |
DOI M ET AL: "Hypoglycemic effect of isoleucine involves increased muscle glucose uptake and whole body glucose oxidation and decreased hepatic gluconeogenesis", AMERICAN JOURNAL OF PHYSIOLOGY - ENDOCRINOLOGY AND METABOLISM, vol. 292, no. 6, June 2007 (2007-06-01), US, pages E1683 - E1693, XP002665728, ISSN: 0193-1849, DOI: 10.1152/AJPENDO.00609.2006 * |
DOI M ET AL: "Isoleucine, a potent plasma glucose-lowering amino acid, stimulates glucose uptake in C2C12 myotubes", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 312, no. 4, 26 December 2003 (2003-12-26), ACADEMIC PRESS INC. ORLANDO, FL, US, pages 1111 - 1117, XP004476391, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2003.11.039 * |
SOLERTE S B ET AL: "Nutritional Supplements with Oral Amino Acid Mixtures Increases Whole-Body Lean Mass and Insulin Sensitivity in Elderly Subjects with Sarcopenia", AMERICAN JOURNAL OF CARDIOLOGY, vol. 101, no. 11, 2 June 2008 (2008-06-02), CAHNERS PUBLISHING CO., NEWTON, MA, US, pages S69 - S77, XP022703181, ISSN: 0002-9149, [retrieved on 20080529], DOI: 10.1016/J.AMJCARD.2008.03.004 * |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
US11733196B2 (en) | 2012-09-11 | 2023-08-22 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
US9483619B2 (en) | 2012-09-11 | 2016-11-01 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
US11131643B2 (en) | 2012-09-11 | 2021-09-28 | Aseko, Inc. | Method and system for optimizing insulin dosages for diabetic subjects |
US10629294B2 (en) | 2012-09-11 | 2020-04-21 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
US10410740B2 (en) | 2012-09-11 | 2019-09-10 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
US10102922B2 (en) | 2012-09-11 | 2018-10-16 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
US9773096B2 (en) | 2012-09-11 | 2017-09-26 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
US9811638B2 (en) | 2012-09-11 | 2017-11-07 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
US9965596B2 (en) | 2012-09-11 | 2018-05-08 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
US11490837B2 (en) | 2014-01-31 | 2022-11-08 | Aseko, Inc. | Insulin management |
US11783946B2 (en) | 2014-01-31 | 2023-10-10 | Aseko, Inc. | Method and system for insulin bolus management |
US9898585B2 (en) | 2014-01-31 | 2018-02-20 | Aseko, Inc. | Method and system for insulin management |
US9892235B2 (en) | 2014-01-31 | 2018-02-13 | Aseko, Inc. | Insulin management |
US11857314B2 (en) | 2014-01-31 | 2024-01-02 | Aseko, Inc. | Insulin management |
US9965595B2 (en) | 2014-01-31 | 2018-05-08 | Aseko, Inc. | Insulin management |
US11804300B2 (en) | 2014-01-31 | 2023-10-31 | Aseko, Inc. | Insulin management |
US9710611B2 (en) | 2014-01-31 | 2017-07-18 | Aseko, Inc. | Insulin management |
US11621074B2 (en) | 2014-01-31 | 2023-04-04 | Aseko, Inc. | Insulin management |
US10255992B2 (en) | 2014-01-31 | 2019-04-09 | Aseko, Inc. | Insulin management |
US9233204B2 (en) | 2014-01-31 | 2016-01-12 | Aseko, Inc. | Insulin management |
US11468987B2 (en) | 2014-01-31 | 2022-10-11 | Aseko, Inc. | Insulin management |
US9604002B2 (en) | 2014-01-31 | 2017-03-28 | Aseko, Inc. | Insulin management |
US10453568B2 (en) | 2014-01-31 | 2019-10-22 | Aseko, Inc. | Method for managing administration of insulin |
US10535426B2 (en) | 2014-01-31 | 2020-01-14 | Aseko, Inc. | Insulin management |
US9504789B2 (en) | 2014-01-31 | 2016-11-29 | Aseko, Inc. | Insulin management |
US10811133B2 (en) | 2014-01-31 | 2020-10-20 | Aseko, Inc. | System for administering insulin boluses to a patient |
US11311213B2 (en) | 2014-01-31 | 2022-04-26 | Aseko, Inc. | Insulin management |
US11081233B2 (en) | 2014-01-31 | 2021-08-03 | Aseko, Inc. | Insulin management |
US11783945B2 (en) | 2014-01-31 | 2023-10-10 | Aseko, Inc. | Method and system for insulin infusion rate management |
US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
US11158424B2 (en) | 2014-01-31 | 2021-10-26 | Aseko, Inc. | Insulin management |
WO2015191533A1 (en) * | 2014-06-13 | 2015-12-17 | East Carolina University | Methods of using carnosinol and analogs thereof |
US11678800B2 (en) | 2014-10-27 | 2023-06-20 | Aseko, Inc. | Subcutaneous outpatient management |
US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
US10403397B2 (en) | 2014-10-27 | 2019-09-03 | Aseko, Inc. | Subcutaneous outpatient management |
US9892234B2 (en) | 2014-10-27 | 2018-02-13 | Aseko, Inc. | Subcutaneous outpatient management |
US10128002B2 (en) | 2014-10-27 | 2018-11-13 | Aseko, Inc. | Subcutaneous outpatient management |
US11694785B2 (en) | 2014-10-27 | 2023-07-04 | Aseko, Inc. | Method and dosing controller for subcutaneous outpatient management |
US11547125B2 (en) | 2015-02-13 | 2023-01-10 | Mars, Incorporated | Pet food feeding system |
US10380328B2 (en) | 2015-08-20 | 2019-08-13 | Aseko, Inc. | Diabetes management therapy advisor |
US11574742B2 (en) | 2015-08-20 | 2023-02-07 | Aseko, Inc. | Diabetes management therapy advisor |
US9886556B2 (en) | 2015-08-20 | 2018-02-06 | Aseko, Inc. | Diabetes management therapy advisor |
US11672263B2 (en) | 2015-12-17 | 2023-06-13 | Mars, Incorporated | Food product for reducing muscle breakdown and methods thereof |
CN108471781A (en) * | 2015-12-17 | 2018-08-31 | 马斯公司 | Reduce the food product and its method of muscle breakdown |
US20210393593A1 (en) * | 2018-09-27 | 2021-12-23 | Societe Des Produits Nestle S.A. | Use of histidine, glycine and other amino acids for preventing insulin resistance and/or diabetes |
WO2021178860A1 (en) * | 2020-03-06 | 2021-09-10 | Axcella Health Inc. | Amino acid compositions and methods for muscle and myotube modulation |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7879796B2 (en) | Amino acid composition for improving glucose tolerance | |
WO2012047800A1 (en) | Methods for increasing muscle glucose uptake and decreasing muscle recovery time using amino acid blend | |
CN109222103B (en) | Muscle-building composition and health food | |
WO2012097064A1 (en) | Nutritional compositions and methods for controlling blood glucose | |
CA2261708A1 (en) | Composition of pyruvate and protein and method for increasing protein concentration in a mammal | |
WO2012097061A1 (en) | Nutritional compositions and methods for improving skeletal muscle protein metabolism | |
KR20100094485A (en) | Anti-fatigue agent comprising amino acid composition | |
WO2014071176A1 (en) | Nutritional supplements including meal replacements and related methods | |
TWI592153B (en) | Methods of promoting the healing of diabetic ulcers using beta-hydroxy-beta-methylbutyrate with arginine and glutamine | |
US20150025143A1 (en) | Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance | |
JP2001187736A (en) | Nutritive analeptic and nutritive analeptic drink | |
CN104302192A (en) | Reduced calorie infant formulas containing specific whey to casein ratios | |
KR19990035872A (en) | Food composition to lower body fat percentage and improve gymnasticity and how to lower body fat percentage and improve gymnasticity | |
CN107530385A (en) | For promoting composition caused by BDNF | |
MX2007011610A (en) | Amino acid composition for improving glucose tolerance | |
CN107249615B (en) | Hot flash inhibitor | |
CA3234362A1 (en) | Compositions and methods using an autophagy inducer to enhance intermittent fasting | |
JP2003321352A (en) | Composition containing coenzyme q10 | |
JP4709120B2 (en) | Composition for promoting growth hormone secretion | |
TW201825011A (en) | Composition for improving protein efficiency ratio | |
KR20200139919A (en) | Composition for preventing or treating obesity comprising parasitic helminth total lysate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11773605 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11773605 Country of ref document: EP Kind code of ref document: A1 |